Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Loxo Oncology
Loxo Oncology
Day One of JPM Brings Excitement and Promise for a New Year in Biotech and Pharma
BioSpace
Wed, 01/9/19 - 09:40 am
JPMHC 2019
M&A
Eli Lilly
Loxo Oncology
SAGE Therapeutics
Sanofi
Regeneron
Bristol-Myers Squibb
Celgene
Novartis
Gilead Sciences
Is Eli Lilly Overpaying for Loxo Oncology?
Motley Fool
Tue, 01/8/19 - 09:30 am
Eli Lilly
Loxo Oncology
M&A
Vitrakvi
Eli Lilly to buy Loxo Oncology for $8 billion in huge bet on cancer genetics
Stat
Mon, 01/7/19 - 10:09 am
Eli Lilly
Loxo Oncology
M&A
5 Things You Need to Know About Loxo Oncology's Revolutionary New Cancer Drug
Motley Fool
Wed, 11/28/18 - 10:08 am
Loxo Oncology
Vitrakvi
Shattering an old record, FDA quickly OKs pioneering, site-agnostic cancer drug larotrectinib from Loxo and Bayer
Endpoints
Mon, 11/26/18 - 05:53 pm
FDA
larotrectinib
Bayer
Loxo Oncology
oncology
personalized medicine
Loxo's targeted therapy holds up to Roche challenge
Biopharma Dive
Sun, 10/21/18 - 11:36 pm
Roche
entrectinib
Loxo Oncology
Ignyta
Bayer
larotrectinib
3 Biotechs Awaiting FDA Approval Decisions
Motley Fool
Tue, 10/16/18 - 11:52 am
FDA
TherapeuticsMD
TX-001HR
AcelRx
Dsuvia
Loxo Oncology
larotrectinib
Cancer drug rivals at Loxo and Blueprint go toe-to-toe once again, and one analyst scores a (possible) win on points
Endpoints
Mon, 10/8/18 - 09:58 am
Loxo Oncology
Blueprint Medicines
medullary thyroid cancer
LOXO-292
BLU-667
FDA waves Loxo through for second ‘breakthrough’ in tissue-agnostic cancer therapy
Endpoints
Wed, 09/5/18 - 10:32 am
Loxo Oncology
FDA
breakthrough status
LOXO-292
Highly anticipated trial results expected soon could move all three of these biotechs
Motley Fool
Mon, 09/3/18 - 12:07 pm
Sangamo Therapeutics
Esperion Therapeutics
Loxo Oncology
SB-913
bempedoic acid
LOXO-292
ASCO18: Who were the big winners and losers?
Biopharma Dive
Wed, 06/6/18 - 04:06 pm
ASCO 2018
Merck
Loxo Oncology
Bluebird Bio
Celgene
Roche
Nektar
#ASCO18: A Weekend of Surprises
Motley Fool
Sun, 06/3/18 - 09:13 pm
ASCO 2018
Bluebird Bio
Loxo Oncology
Nektar Therapeutics
Celgene
Grail
Loxo Unveils More Data, Paves a Path Forward In Precision Oncology
Xconomy
Sat, 06/2/18 - 11:31 am
Loxo Oncology
LOXO-292
ASCO 2018
clinical trials
FDA starts speedy review of Loxo’s site-agnostic cancer drug larotrectinib
Fierce Biotech
Tue, 05/29/18 - 11:41 am
FDA
Loxo Oncology
Bayer
metastatic solid tumors
larotrectinib
The Week Ahead In Biotech: ASCO Presentations In The Spotlight
Yahoo/Benzinga
Mon, 05/28/18 - 02:14 pm
ASCO 2018
European Society of Cardiology
TherapeuticsMD
Abiomed
Incyte
Bluebird Bio
Celgene
Syndax
Loxo Oncology
Exelixis
Karyopharm
Endocyte
Celldex Therapeutics
Jounce Therapeutics
Bristol-Myers Squibb
Nektar
Does a Blue Ribbon Make This Biotech Stock a Buy Now?
Motley Fool
Sat, 05/19/18 - 11:18 am
Loxo Oncology
ASCO
LOXO-292
Winners and Losers From the Biggest Cancer Meeting of the Year (So Far)
Motley Fool
Fri, 05/18/18 - 10:00 pm
ASCO
Endocyte
Loxo Oncology
Blueprint Medicines
Nektar Therapeutics
Jounce Therapeutics
5 takeaways from the first look at cancer's biggest conference
Biopharma Dive
Thu, 05/17/18 - 10:44 pm
ASCO
Regeneron
cemiplimab
Keytruda
Opdivo
Merck
Bristol-Myers Squibb
Nektar
NKTR-214
Loxo Oncology
LOXO-292
Jounce Therapeutics
JTX-2011
3 Biotech Stocks to Be Thankful for This Year
Yahoo/Motley Fool
Mon, 11/20/17 - 09:30 am
biotech
Loxo Oncology
Nektar
Spectrum Pharmaceuticals
[video]Is Loxo Oncology's Deal With Bayer Bad News?
Motley Fool
Sat, 11/18/17 - 04:23 pm
Loxo Oncology
Bayer
larotrectinib
Pages
« first
‹ previous
1
2
3
next ›
last »